Zobrazeno 1 - 10
of 603
pro vyhledávání: '"F. Schellhammer"'
Autor:
F. Schellhammer
Publikováno v:
Atemwegs- und Lungenkrankheiten. 49:186-188
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 39:514-520
This narrative of the history of the Society of Urologic Oncology (SUO) presents the story of the founding and development of this organization and the creation and establishment of its initiatives and programs. It includes a description of how "Urol
Publikováno v:
Clinical Genitourinary Cancer. 18:416-422
Background Numerous globally approved castration-resistant prostate cancer (CRPC) therapies are available. Enzalutamide and radium 223 (Ra 223) are approved for survival prolongation and ability to delay radiographic progression. Both have markedly d
Autor:
Ronald F. Tutrone, Andrew J. Armstrong, Oliver Sartor, Paul F. Schellhammer, Matthew Harmon, Stephen J. Freedland, David I. Quinn, Neal D. Shore, Arif Hussain, David G. McLeod, Philip W. Kantoff, Nicholas J. Vogelzang, Matthew R. Cooperberg, Nadeem A. Sheikh, Chiledum Ahaghotu, Eric J. Small, Celestia S. Higano, David F. Penson, Elisabeth I. Heath, Nancy N. Chang, Christopher Michael Pieczonka, Bruce Brown
Publikováno v:
Prostate Cancer and Prostatic Diseases
Prostate cancer and prostatic diseases, vol 23, iss 3
Prostate cancer and prostatic diseases, vol 23, iss 3
Purpose African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T.
Autor:
Paul F. Schellhammer, Richard Moriarty
Publikováno v:
Cancer Screening ISBN: 9780429179587
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24e6e4fcdeff69dba78293610891bae3
https://doi.org/10.1201/9780429179587-11
https://doi.org/10.1201/9780429179587-11
Autor:
Donald F. Lynch, Paul F. Schellhammer
Publikováno v:
The Scientific World Journal, Vol 4, Pp 179-191 (2004)
Externí odkaz:
https://doaj.org/article/784706ad03944140a721c771b9615f03
Autor:
Celestia S. Higano, David G. McLeod, Neal D. Shore, Louis Denis, Mario A. Eisenberger, E. David Crawford, Fernand Labrie, Paul F. Schellhammer, Judd W. Moul, Peter Iversen
Publikováno v:
Journal of Urology. 200:956-966
Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of antiandrogens in the treatment of prostate cancer.We
Autor:
A., Vantorre, F., Schellhammer
Publikováno v:
German Journal of Sports Medicine / Deutsche Zeitschrift fur Sportmedizin; 2022, Vol. 73 Issue 2, p77-80, 4p
Autor:
Paul F. Schellhammer, David I. Quinn, Ronald F. Tutrone, Arif Hussain, Celestia S. Higano, David G. McLeod, Christopher Michael Pieczonka, Neal D. Shore, Nancy N. Chang, Elisabeth I. Heath, Matthew Harmon, Chiledum Ahaghotu, Stephen J. Freedland, Philip W. Kantoff, Andrew J. Armstrong, Oliver Sartor, David F. Penson, Nicholas J. Vogelzang, Matthew R. Cooperberg
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 29:D084-D084
BACKGROUND: Prostate cancer risk and mortality are higher in AAs versus CAUs. Post-hoc analyses of pooled Phase 3 data (n = 737) suggested substantial OS benefit for AA men receiving sipuleucel-T (n=33) vs placebo (n = 10) (McLeod 2012). Compared wit
Publikováno v:
Journal of Urology. 199